Randomized Controlled Trial of Rituximab and Cost‐Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome
Top Cited Papers
Open Access
- 10 March 2017
- journal article
- research article
- Published by Wiley in Joint Bone Spine
- Vol. 69 (7), 1440-1450
- https://doi.org/10.1002/art.40093
Abstract
Objective To investigate whether rituximab, an anti–B cell therapy, improves symptoms of fatigue and oral dryness in patients with primary Sjögren's syndrome (SS). Methods We conducted a multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial that included health economic analysis. Anti‐Ro–positive patients with primary SS, symptomatic fatigue, and oral dryness were recruited from 25 UK rheumatology clinics from August 2011 to January 2014. Patients were centrally randomized to receive either intravenous (IV) placebo (250 ml saline) or IV rituximab (1,000 mg in 250 ml saline) in 2 courses at weeks 0, 2, 24, and 26, with pre‐ and postinfusion medication including corticosteroids. The primary end point was the proportion of patients achieving a 30% reduction in either fatigue or oral dryness at 48 weeks, as measured by visual analog scale. Other outcome measures included salivary and lacrimal flow rates, quality of life, scores on the European League Against Rheumatism (EULAR) Sjögren's Syndrome Patient Reported Index and EULAR Sjögren's Syndrome Disease Activity Index, symptoms of ocular and overall dryness, pain, globally assessed disease activity, and cost‐effectiveness. Results All 133 patients who were randomized to receive placebo (n = 66) or rituximab (n = 67) were included in the primary analysis. Among patients with complete data, 21 of 56 placebo‐treated patients and 24 of 61 rituximab‐treated patients achieved the primary end point. After multiple imputation of missing outcomes, response rates in the placebo and rituximab groups were 36.8% and 39.8%, respectively (adjusted odds ratio 1.13 [95% confidence interval 0.50, 2.55]). There were no significant improvements in any outcome measure except for unstimulated salivary flow. The mean ± SD costs per patient for rituximab and placebo were £10,752 ± 264.75 and £2,672 ± 241.71, respectively. There were slightly more adverse events (AEs) reported in total for rituximab, but there was no difference in serious AEs (10 in each group). Conclusion The results of this study indicate that rituximab is neither clinically effective nor cost‐effective in this patient population.Keywords
Funding Information
- Arthritis Research UK
This publication has 26 references indexed in Scilit:
- Effects of Hydroxychloroquine on Symptomatic Improvement in Primary Sjögren SyndromeJAMA, 2014
- Rituximab Therapy for Primary Sjögren's Syndrome: An Open‐Label Clinical Trial and Mechanistic AnalysisArthritis & Rheumatism, 2013
- Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up studyArthritis Research & Therapy, 2013
- Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot studyAnnals Of The Rheumatic Diseases, 2008
- Improvement of Sjögren's syndrome after two infusions of rituximab (anti‐CD20)Arthritis Care & Research, 2007
- Rituximab treatment in patients with primary Sjögren's syndrome: An open‐label phase II studyArthritis & Rheumatism, 2005
- Successful Treatment of Dry Mouth and Dry Eye Symptoms in Sjögren's Syndrome Patients With Oral PilocarpineJCR: Journal of Clinical Rheumatology, 2004
- Measurement of fatigue and discomfort in primary Sjögren's syndrome using a new questionnaire toolRheumatology, 2004
- Update in Sjögren syndromeCurrent Opinion in Rheumatology, 2000
- Pilocarpine Tablets for the Treatment of Dry Mouth and Dry Eye Symptoms in Patients With Sjögren SyndromeA Randomized, Placebo-Controlled, Fixed-Dose, Multicenter TrialArchives of Internal Medicine, 1999